Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer.

Based on in vitro evidence of radiosensitization by Betaseron (beta-IFN), a Phase I/II study was undertaken to determine toxicity and response using combined radiation (RT) and B-IFN in patients with unresectable Stage III and nonsmall cell lung cancer.
Varying doses of beta-IFN(10 to 90 x 10(6) IU) were administered IV immediately preceding RT on the first three days of weeks 1, 3, and 5. The RT dose was 1.8 Gy/day, 5 days/week for a total of 54 or 59.4 Gy.
Thirty-nine patients were entered, 32 of whom were evaluable. The median follow-up time at time of analysis was 60 months. Responses were based on CT scan. The response rate for the total group was 81% with 44% achieving complete response. Seventy-eight percent of patients with complete response survived a minimum of 21 months. Twenty-six patients had Stage III A/B disease with a median tumor size of 6.5 cm. and median survival was 19.7 months. The 5-year actuarial survival for this group was 31%, with a plateau persisting after 3 years. There were no treatment related deaths nor any event of life threatening toxicity. Of eight patients surviving 3-5 years, no long-term toxicity has been observed. Karnofsky indices were 90-100 and respiratory symptoms were minimal.
beta-IFN is well-tolerated. Response and survival rates are sufficiently encouraging to warrant further investigation in a randomized trial which has been accepted as an RTOG study awaiting drug availability.
AuthorsS McDonald, A Y Chang, P Rubin, J Wallenberg, I S Kim, S Sobel, J Smith, P Keng, A Muhs
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 27 Issue 3 Pg. 613-9 (Oct 20 1993) ISSN: 0360-3016 [Print] UNITED STATES
PMID8226156 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Recombinant Proteins
  • Interferon beta-1b
  • Interferon-beta
  • Interferon beta-1a
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung (mortality, physiopathology, radiotherapy, therapy)
  • Combined Modality Therapy
  • Female
  • Humans
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-beta (adverse effects, therapeutic use)
  • Lung (physiopathology)
  • Lung Neoplasms (mortality, physiopathology, radiotherapy, therapy)
  • Male
  • Middle Aged
  • Radiotherapy Dosage
  • Recombinant Proteins (adverse effects, therapeutic use)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: